The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | A comparative study of D-Rd and VRd based on the MAIA and SWOG S0777 trials
Brian Durie, MD, Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA, discusses a comparison of daratumumab, lenalidomide, and dexamethasone (D-Rd) to bortezomib, lenalidomide, and dexamethasone (VRd) using data from the SWOG S0777 (NCT00644228) and MAIA (NCT02252172) trials. The findings show that D-Rd can be administered for longer, while VRd often needs to be stopped due to the risk of neuropathy, making D-Rd a more suitable option, particularly for older and frail patients. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
